High-dose immunosuppressive therapy with or without hematopoietic transplantation for the treatment of multiple sclerosis
Record ID 32010000991
English
Authors' objectives:
Treatment with high-dose immunosuppressive therapy (HDIT) has been used as a diseasemodifying therapy in many severe autoimmune conditions, including multiple sclerosis. The immunosuppressive drug or combination of drugs is administered at a dosage that approaches or exceeds myeloablative levels. Hematopoietic stem cells harvested either from peripheral blood or bone marrow is used to rescue the hematopoietic system after myeloablation. The ultimate goal of the treatment is to eliminate self-reactive lymphocytes from the patient and regenerate an immune system tolerant to its host.
Details
Project Status:
Completed
URL for project:
http://www.hayesinc.com
Year Published:
2010
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Immunosuppressive Agents
- Multiple Sclerosis
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2010 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.